The Collaboration Agreement creates the opportunity for physicians and adult patients to gather experience in a real-world setting with the ABILIFY MYCITE System.

The ABILIFY MYCITE System provides an opportunity for a connected care approach to treatment, and tracks if ABILIFY MYCITE (aripiprazole tablet with sensor) has been taken. The system is comprised of: the ABILIFY MYCITE tablet (an aripiprazole tablet embedded with an Ingestible Event Marker (IEM) sensor); the MYCITE Patch (a wearable sensor); the MYCITE APP (a smartphone application) and the MYCITE Dashboard (a web-based portal for healthcare providers and caregivers). Please see About the ABILIFY MYCITE System and IMPORTANT SAFETY INFORMATION for ABILIFY MYCITE below.

Otsuka North America Pharmaceutical Business president and CEO Kabir Nath said: “We are confident that being able to track drug ingestion in patients with serious mental illness will provide compelling insights for patients and their healthcare provider teams. We are eager for patients, doctors and the healthcare community to experience the ABILIFY MYCITE System in a real-world setting.

“This Collaboration Agreement is an important milestone in our initial rollout of the ABILIFY MYCITE System to market. We look forward to collaborating with additional payer groups to continue learning as we move toward a data-driven treatment approach.”

The initial rollout of the ABILIFY MYCITE System is purposeful and patients in select regional provider networks contracted through Magellan Health will receive the opportunity to opt in to this program.

By focusing on fewer individuals using the ABILIFY MYCITE System at first, Otsuka and Magellan Health will be better able to understand how it fits within the daily lives of those with serious mental illness and their caregivers, how doctors will integrate it into their daily practice and how patients may benefit from more information about their care.

As a result, Otsuka will be able to consider ways to improve the ABILIFY MYCITE System to enhance the experience and better serve prospective patients, their caregivers, and physicians in the future.

Magellan Healthcare CEO Sam K. Srivastava said: “Our collaboration with Otsuka is a natural progression for Magellan Health in providing next-generation precision medicine that can empower individuals with serious mental illness.

“The opportunity for new insights to drive personalized care for the individual will also allow us to enhance our digital tools and care management model that we offer for our members. This collaboration aligns with our purpose of leading humanity to healthy, vibrant lives through a joint commitment to improving patient outcomes for complex populations.”

Otsuka and Magellan Health look forward to bringing the ABILIFY MYCITE System to patients. More details will be shared in the coming months as the ABILIFY MYCITE System is integrated into certain healthcare environments.

Thomas Jefferson University, Jefferson College of Population Health Dean and Digital Medicine National Steering Board chairman David B. Nash said: “This strategically aligned collaboration between Otsuka and Magellan Health has the aim of providing real-world evidence to demonstrate the value of this drug/device combination product over time.

“This is an exciting time, from a Population Health perspective, as we gather insights into factors that influence adherence to treatment and consider the related clinical and economic implications.”

Source: Company Press Release.